After Alkermes (ALKS) issued a press release reporting top-line data for the Phase 2 Vibrance-1 trial evaluating once-daily oral alixorexton in narcolepsy type 1, Leerink said the firm views the competitor’s topline NT1 results as “encouraging” for Centessa’s (CNTA) ORX750. The data further validate the orexin agonist class and suggest there may be room for ORX750 to differentiate on efficacy and/or safety, according to the analyst, who keeps an Outperform rating on Centessa shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTA:
- Centessa initiated with a Buy at Truist
- Positive Market Outlook for Centessa Pharmaceuticals Driven by Promising Developments in Orexin Agonist Class
- Optimistic Buy Rating for Centessa Pharmaceuticals Driven by Orexin Agonist Market Potential and Positive Safety Profile
- Centessa Pharmaceuticals Positioned for Leadership in Orexin Agonist Market with Promising ORX750 Candidate
- Centessa Pharmaceuticals Approves Key Resolutions at AGM